IPF Partners

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

Patient21 operates a health platform focused on improving the doctor-patient connection, which they view as essential for effective healthcare. The company aims to modernize the healthcare experience by addressing the fragmented and outdated processes currently prevalent in the industry. By leveraging technology, Patient21 enhances dental clinics with management software that streamlines administrative tasks such as appointment scheduling and patient data management. They also provide electronic health records (EHR) to healthcare professionals, which helps improve diagnostic quality and reduce costs. Through these innovations, Patient21 seeks to facilitate better decision-making for both patients and physicians, ultimately promoting a more personalized and collaborative approach to healthcare.

Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries, utilizing its proprietary Dynamic Surgical Guidance (DSG®) technology. This powerful, radiation-free sensing platform enhances the accuracy and safety of skeletal implant placement through real-time audio and visual feedback for surgeons. The company's flagship product, the PediGuard probe, is specifically designed for spine surgery, allowing surgeons to create pilot holes in vertebrae with precision. Equipped with a sensor that measures electrical conductivity, the PediGuard alerts surgeons to changes in bone and tissue types without the need for X-ray imaging. Available in various shapes and sizes, these devices cater to a wide range of surgical needs, from pediatric deformity corrections to adult degenerative conditions. With over 80,000 successful spinal procedures supported by PediGuard and substantial clinical evidence backing its efficacy, SpineGuard aims to address critical challenges in pedicle screw placement while improving patient outcomes and operational efficiency in the surgical environment.

Genesis Automation specializes in healthcare value-chain solutions aimed at enhancing patient safety and operational efficiency within healthcare organizations. The company has developed a clinical traceability platform that tracks the movement of essential supplies and equipment throughout the healthcare supply chain, from manufacturers to the point of care. By providing a suite of tools designed to ensure the accurate delivery of medication and devices, Genesis Automation helps hospitals and suppliers reduce costs and eliminate waste, ultimately improving the overall quality of patient care.

Genesis Automation is a single source, full-service automated system solutions provider. It designs and builds high-precision assembly, test, and special process equipment for a wide range of industries. Genesis Automation was founded in 1999 and is based in Cork, Ireland.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

Mauna Kea Technologies, established in 2000 and based in Paris, France, specializes in developing and marketing medical devices for cancer and other disease diagnosis and treatment. Its core product, Cellvizio, is a real-time, cellular-level imaging platform used by physicians and researchers worldwide. This platform, based on confocal laser endomicroscopy, enables precise, in vivo visualization of tissues during standard procedures, aiding in early-stage pathology detection and informed therapeutic decisions. The company generates revenue through the sale of Cellvizio products and accessories, serving customers in Europe, the Middle East, Africa, the Americas, and Asia.

Impeto Medical SAS is a privately owned medical device company based in Paris, France, established in 2005. The company specializes in manufacturing and marketing non-invasive devices that assess eccrine sweat gland activity. Its key products include SUDOSCAN+, which detects and monitors peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardiometabolic risks; and SUDOSCAN, which evaluates galvanic skin response to assess the sympathetic nervous system's behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical utilizes patented technology to analyze sudomotor function, enabling healthcare providers to screen large patient populations for early detection of diseases and complications. The company distributes its products through a network of distributors and has subsidiary locations in China and San Diego, California.

Neuravi, established in 2009 and based in Galway, Ireland, specializes in the design and development of clot retrieval devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries, collaborating with international researchers and clinicians to advance understanding and treatment of ischemic stroke. As of 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.

i-Optics, established in 2006, is a Dutch medical device company specializing in corneal diagnostic solutions. It offers the Cassini Corneal Shape Analyzer, a pioneering tool using color LED technology to precisely measure corneal astigmatism, enhancing premium IOL planning. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system for diagnosing retinal diseases. Their suite of examinations, including corneal topography, pupillometry, and full-color photography, empowers cataract surgeons to better understand corneal properties, improve surgical outcomes, and increase patient satisfaction.

Genesis Automation specializes in healthcare value-chain solutions aimed at enhancing patient safety and operational efficiency within healthcare organizations. The company has developed a clinical traceability platform that tracks the movement of essential supplies and equipment throughout the healthcare supply chain, from manufacturers to the point of care. By providing a suite of tools designed to ensure the accurate delivery of medication and devices, Genesis Automation helps hospitals and suppliers reduce costs and eliminate waste, ultimately improving the overall quality of patient care.

SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries, utilizing its proprietary Dynamic Surgical Guidance (DSG®) technology. This powerful, radiation-free sensing platform enhances the accuracy and safety of skeletal implant placement through real-time audio and visual feedback for surgeons. The company's flagship product, the PediGuard probe, is specifically designed for spine surgery, allowing surgeons to create pilot holes in vertebrae with precision. Equipped with a sensor that measures electrical conductivity, the PediGuard alerts surgeons to changes in bone and tissue types without the need for X-ray imaging. Available in various shapes and sizes, these devices cater to a wide range of surgical needs, from pediatric deformity corrections to adult degenerative conditions. With over 80,000 successful spinal procedures supported by PediGuard and substantial clinical evidence backing its efficacy, SpineGuard aims to address critical challenges in pedicle screw placement while improving patient outcomes and operational efficiency in the surgical environment.

Mainstay Medical, based in Dublin, Ireland, with operations in the U.S. and Australia, is a medical device company specializing in the development and commercialization of innovative treatments for chronic low back pain. Its flagship product, ReActiv8, is an implantable neurostimulation system designed to restore muscle control and improve function in the lumbar spine, thereby enhancing patients' quality of life. Founded in 2008, the company collaborates with scientists and clinical experts to address the significant unmet need in this large, underserved patient population.

i-Optics, established in 2006, is a Dutch medical device company specializing in corneal diagnostic solutions. It offers the Cassini Corneal Shape Analyzer, a pioneering tool using color LED technology to precisely measure corneal astigmatism, enhancing premium IOL planning. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system for diagnosing retinal diseases. Their suite of examinations, including corneal topography, pupillometry, and full-color photography, empowers cataract surgeons to better understand corneal properties, improve surgical outcomes, and increase patient satisfaction.

EOS Imaging SA is a medical technology company based in Paris, France, specializing in low-dose 2D/3D imaging and software solutions for osteo-articular conditions and orthopedic surgeries. The company develops and markets the EOS imaging system, which produces full-body, stereo-radiographic images of patients in functional positions, tailored to the specific needs of orthopedic surgeons and radiologists. Its product offerings include EOSedge, a high-quality X-ray system, sterEOS, a 3D modeling workstation for precise skeletal analysis, and EOSapps, online surgical planning solutions based on real-time imaging. Additionally, EOS Imaging creates planning software for knee and hip surgeries and manufactures patient-specific cutting guides for orthopedic procedures. The company operates globally, with a presence in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America, and has obtained marketing authorization for its systems in 48 countries. Founded in 1989, EOS Imaging was previously known as biospace med before rebranding in 2010.

Mendor is a Finnish company focused on designing, developing, and marketing innovative diabetes management products. It has introduced a portable, all-in-one blood glucose meter alongside a web-based software application aimed at facilitating daily diabetes management. Mendor's products are developed in collaboration with users and diabetes experts to meet the specific needs of individuals who require regular blood glucose monitoring. Additionally, the company offers patented software systems that provide real-time data on diabetic care, which enhances the efficacy and efficiency of diabetes treatment for both patients and caregivers.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.